Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 12/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.64 |
| ▸ | QPCT | Q16769 | 1/20 | 0.64 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.64 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448042 | 1.00 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL394308 | 0.88 | CYP11B1 (0.83) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL24733003 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL28802722 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL10997898 | 0.80 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL9661609 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL1848631 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL12205 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL9747422 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL12299569 | 0.80 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| EP-3714012-B1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2023-01-11 | — | — | EP | disclosed |
| US-20210102093-A1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2021-04-08 | — | — | US | disclosed |
| US-10899945-B2 | Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates | BASF SE (DE) | 2021-01-26 | — | — | US | disclosed |
| EP-3714012-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200299547-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2020-09-24 | — | — | US | disclosed |
| EP-3334794-B1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-1436269-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| WO-2003033482-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| EP-0612731-B1 | Novel guinolone and naphthyridone derivatives | BAYER AG (DE) | 1997-08-20 | — | — | EP | disclosed |
| EP-0612731-A1 | Novel guinolone and naphthyridone derivatives | BAYER AG (DE) | 1994-08-31 | — | — | EP | disclosed |
| US-4873238-A | ANTIULCER AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-10-10 | — | — | US | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CYP11B1 81/4885CYP11B2 50/4885ADRA2C 40/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | CYP11B1 3376/4885CYP11B2 3746/4885ADRA2C 4264/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CYP11B1 82/4885CYP11B2 48/4885ADRA2C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.